Skip to main content

Intercept Pharmaceuticals, Inc. (ICPT)

NASDAQ: ICPT · IEX Real-Time Price · USD
17.09
-0.04 (-0.23%)
After-hours:Oct 22, 2021 7:13 PM EDT
17.13
0.23 (1.36%)
At close: Oct 22, 4:00 PM
Market Cap480.53M
Revenue (ttm)341.03M
Net Income (ttm)-170.13M
Shares Out33.18M
EPS (ttm)-5.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume354,097
Open16.74
Previous Close16.90
Day's Range16.30 - 17.17
52-Week Range11.60 - 40.41
Beta1.43
AnalystsBuy
Price Target29.61 (+72.9%)
Est. Earnings DateOct 28, 2021

About ICPT

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in vario...

IndustryBiotechnology
IPO DateOct 11, 2012
Employees498
Stock ExchangeNASDAQ
Ticker SymbolICPT
Full Company Profile

Financial Performance

In 2020, ICPT's revenue was $312.69 million, an increase of 24.08% compared to the previous year's $252.00 million. Losses were -$274.88 million, -20.25% less than in 2019.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for ICPT stock is "Buy." The 12-month stock price forecast is 29.61, which is an increase of 72.85% from the latest price.

Price Target
$29.61
(72.85% upside)
Analyst Consensus: Buy

News

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) and Encourages L...

Philadelphia, Pennsylvania--(Newsfile Corp. - October 23, 2021) - Kaskela Law LLC announces that it is investigating Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) on beha...

5 hours ago - Newsfile Corp

Wall Street Analysts Think Intercept (ICPT) Could Surge 95%: Read This Before Placing a Bet

The mean of analysts' price targets for Intercept (ICPT) points to a 94.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

1 week ago - Zacks Investment Research

7 Meme Stocks With Short-Squeeze Potential In October

Meme stocks are seeing a sudden increase in volume and price. Here are seven of the best meme stocks to buy.

3 weeks ago - InvestorPlace

7 Short-Interest Stocks That Could Be Bull Traps

While betting on short-interest stocks has become a popular speculation tactic, you want to be careful about this fad. The post 7 Short-Interest Stocks That Could Be Bull Traps appeared first on Investo...

1 month ago - InvestorPlace

Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pr...

1 month ago - GlobeNewsWire

3 Most-Shorted Stocks to Buy

Off and on the price chart, these three most-shorted stocks – found after we've searched high and low – have the goods to rally. The post 3 Most-Shorted Stocks to Buy appeared first on InvestorPlace.

Other symbols:BGFVSPWR
1 month ago - InvestorPlace

5 Stocks With 195% to 467% Upside, According to Wall Street

If these high-water price targets come to fruition, investors will be all smiles.

Other symbols:AMRNINOPLUGZGNX
1 month ago - The Motley Fool

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest This Week

We're seeing loads of interest from investors targeting short-squeeze stocks this week as meme rallies push several shares higher. The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest T...

1 month ago - InvestorPlace

Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference

NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pr...

1 month ago - GlobeNewsWire

Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeuti...

2 months ago - GlobeNewsWire

5 Growth Stocks With 110% to 393% Upside, According to Wall Street

Analysts are calling for significant gains in these fast-paced stocks.

Other symbols:BIDUCOINNIO
2 months ago - The Motley Fool

Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat

Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.

2 months ago - Zacks Investment Research

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

Intercept (ICPT) delivered earnings and revenue surprises of 73.39% and 16.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Intercept Pharmaceuticals: Q2 Earnings Insights

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) moved higher by 3.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 82.81% year over year to ($0...

2 months ago - Benzinga

Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter

2 months ago - GlobeNewsWire

Earnings Outlook For Intercept Pharmaceuticals

Intercept Pharmaceuticals (NASDAQ:ICPT) unveils its next round of earnings this Thursday, July 29. Get prepared with Benzinga's ultimate preview for Intercept Pharmaceuticals's Q2 earnings.

2 months ago - Benzinga

Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021

The biotech can't seem to catch a break.

3 months ago - The Motley Fool

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...

3 months ago - GlobeNewsWire

Intercept to Present at the Raymond James 2021 Human Health Innovation Conference

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...

4 months ago - GlobeNewsWire

Are These the Next Meme Stocks?

Reddit's retail investors may soon be swooning over this under-the-radar trio of heavily short-sold companies.

Other symbols:BLNKPLAY
4 months ago - The Motley Fool

Intercept Appoints M. Michelle Berrey, M.D.

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...

4 months ago - GlobeNewsWire

Intercept (ICPT) Moves 8% Higher: Will This Strength Last?

Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength do...

4 months ago - Zacks Investment Research

Intercept (ICPT) Ocaliva's Prescribing Information Updated

Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.

4 months ago - Zacks Investment Research

Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information

New contraindication applies to a subset of patients with primary biliary cholangitis (PBC) with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of...

4 months ago - GlobeNewsWire